Xtampza ER's growth prospects will make up for Nucynta’s downfall.
The company is demonstrating robust commercial execution.
Investors, however, should consider certain risks.
Today, we will be studying why Collegium Pharmaceutical (COLL) is an attractive pick in 2020, despite being an opioid player.
Collegium Pharmaceutical is a specialty pharmaceutical company with a focus on